Loading: 100%
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reasons:
- It is not known how cost items are reported in the original P&L
- Not all line items from the original statement have been associated with a standardised figure (12 items missing)
No data available for the selected time periods
in million USD H1 '15H2 '15H1 '16
Collaboration revenues
3
n/a
2
Research and development
16
n/a
17
General and administrative
6
n/a
4
Operating expenses total
22
n/a
21
Loss from operations
-18
n/a
-19
Interest expense, net
1
n/a
1
Loss before income taxes
-19
n/a
-20
Income tax expense (benefit)
0
n/a
0
Net loss
-19
n/a
-20
Accretion of redeemable preferred stock and noncontrolling interests
-2
n/a
-2
Deemed dividends upon the repurchase of Series A redeemable preferred stock and redeemable noncontrolling interests
-1
n/a
0
Net loss attributable to common stockholders of Oncobiologics, Inc.
-22
n/a
-22
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (37 items missing)
No data available for the selected time periods
in million USD H1 '15H2 '15H1 '16
Assets
Cash
n/a
9
3
Accounts receivable
n/a
0
1
Stock subscription receivable
n/a
4
0
Related party receivable
n/a
0
0
Prepaid and other current assets
n/a
2
1
Total current assets
n/a
15
4
Property and equipment, net
n/a
18
17
Restricted cash
n/a
0
0
Deferred offering costs
n/a
1
2
Other assets
n/a
1
1
Total assets
n/a
35
25
Liabilities and owners' equity
Current portion of debt
n/a
1 742646
1 760013
Current portion of capital lease obligations
n/a
1 862849
1 907274
Current portion of stockholder notes
n/a
14 14214196
10 9653401
Accounts payable
n/a
12 11563055
14 14416288
Accrued expenses
n/a
6 5924648
6 6403971
Income taxes payable
n/a
2 1754629
2 1854629
Deferred revenue
n/a
2 1979576
2 1979576
Total current liabilities
n/a
37 37041599
36 35975152
Long-term debt
n/a
3 2922764
3 2547139
Capital lease obligations
n/a
1 1219373
1 810122
Stockholder notes
n/a
2 2000000
0 0
Deferred revenue
n/a
6 6365945
5 5376157
Stock-based compensation liability
n/a
13 12726722
0 0
Other liabilities
n/a
0 284710
1 591128
Total liabilities
n/a
63 62561113
45 45299698
Redeemable common stock -1,739,130 shares issued and outstanding
n/a
15 15426673
17 17396626
Redeemable noncontrolling interests
n/a
2 1703777
0 0
Total redeemable preferred stock, common stock and noncontrolling interests
n/a
27 27321311
17 17396626
Series A preferred stock, par value $0.01 per share: 10,000,000 shares authorized, 11,819 shares issued and outstanding at March 31, 2016 (liquidation preference of $11,819,000 at
n/a
0 0
0 118
Common stock value
n/a
40 39844900
0 0
Additional paid-in capital
n/a
0 0
76 76481615
Accumulated deficit
n/a
-94 -94064286
-114 -114470878
Total Oncobiologics, Inc. stockholders' equity (deficit)
n/a
-54 -54219386
-38 -37864873
Non controlling interests
n/a
-1 -654417
0 0
Total stockholders' equity (deficit)
n/a
-55 -54873803
-38 -37864873
Total liabilities, redeemable preferred stock, common stock, noncontrolling interests and stockholders' equity (deficit)
n/a
35 35008621
25 24831451
Remarks restated on n/a restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (30 items missing)
No data available for the selected time periods
in million USD H1 '15H2 '15H1 '16
Net loss
-19
n/a
-20
Depreciation and amortization
0
n/a
1
Non-cash interest expense
0
n/a
0
Stock-based compensation
7
n/a
-2
Loss on disposal of fixed assets
0
n/a
0
Accounts receivable
-1
n/a
0
Prepaid expenses and other current assets
0
n/a
1
Other assets
0
n/a
0
Accounts payable
3
n/a
2
Accrued expenses
1
n/a
0
Income taxes payable
0
n/a
0
Deferred revenue
2
n/a
-1
Other liabilities
0
n/a
0
Net cash used in operating activities
-6
n/a
-19
Purchase of property and equipment
-2
n/a
0
Net cash used in investing activities
-2
n/a
0
Repurchase of Series A redeemable preferred stock
0
n/a
0
Proceeds from the sale of common stock
0
n/a
16
Proceeds from subscriptions receivable
0
n/a
4
Proceeds from stockholders notes
8
n/a
0
Payments of capital leases obligations
0
n/a
0
Repayment of debt
0
n/a
0
Payment of deferred offering costs
0
n/a
0
Repayment of stockholder notes
-1
n/a
-7
Change in restricted cash
0
n/a
0
Proceeds from related party receivable
0
n/a
1
Deconsolidation of Sonnet Biotherapeutics, Inc.
0
n/a
0
Payment of employee tax witholdings related to the vesting of restricted stock
0
n/a
0
Net cash provided by financing activities
7
n/a
13
Net Decrease in Cash
-2
n/a
-6
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Sumo